穴位中药贴治疗原发性痛经:随机对照试验研究方案
本方案为随机、单中心、安慰剂对照临床试验,拟纳入180例原发性痛经患者,按1:1:1随机分为穴位中药贴组、穴位安慰剂贴组和等待名单对照组,以VAS疼痛强度为主要结局,评估穴位中药贴的疗效与安全性。
要点
- 三臂设计可区分穴位中药贴的特异性效应与非特异性效应。
- 主要结局为VAS疼痛强度变化,次要结局包括CMSS、SF-12和PGIC。
- 试验注册号ChiCTR-TRC-16008701,2016年7月22日注册。
核心结论
- 该研究旨在评估穴位中药贴对比穴位安慰剂贴及等待名单对照在原发性痛经患者中的疗效与安全性。
研究设计与样本
- 随机、单中心、安慰剂对照临床试验,计划纳入180例原发性痛经患者,按1:1:1随机分为穴位中药贴组、穴位安慰剂贴组和等待名单对照组。
- 穴位中药贴组使用少腹逐瘀汤贴敷于神阙、关元、气海、次髎和子宫穴,安慰剂组在相同穴位使用安慰剂贴,等待名单组在研究完成前不干预。
关键数值与推荐
- 主要结局为视觉模拟量表(VAS)测量的疼痛强度降低,次要结局包括Cox月经症状量表(CMSS)、12项简短健康调查(SF-12)和参与者总体印象变化(PGIC)。
- 所有评估在基线、治疗期间每个月经周期及随访期间进行,全程记录不良事件。
临床怎么用
- 若试验证实有效,穴位中药贴可能为原发性痛经提供一种补充替代治疗选择。
局限性
- 原文未报告研究结果,无法评估穴位中药贴的实际疗效与安全性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Primary dysmenorrhea (PD), is one of main gynecological complaints in women of child-bearing age. Common medications for PD do not always achieve satisfactory outcome of pain relief. Hence, both health professionals and patients are seeking help from complementary and alternative medicine. The acupoint herbal plaster (AHP), which appears to be a safe and effective way to alleviate menstrual pain, as well as to improve other PD-related symptoms. Despite similar clinical studies for this condition in the past, no high-quality methodology-based clinical trial has been reported to date. The current study aims to assess the efficacy of the AHP compared with the acupoint placebo plaster (APP) and being placed on a waiting-list control group in patients with primary dysmenorrhea. METHODS/DESIGN: This study is a randomized, single-center, placebo-controlled clinical trial. A total of 180 women with PD will be included and randomly allocated to the AHP, APP and waiting-list (WL) groups in a 1:1:1 ratio. Patients in the AHP group will be provided with herbal plasters (Shaofuzhuyu decoction) on various acupoints: Shenque (CV8), Guanyuan (CV4), Qihai (CV5), Ciliao (BL32) and Zigong (EX-CA1). Women in the APP group will receive placebo plasters on the same acupoints, and no intervention will be given to the WL group until completion of the study. The primary outcome will be pain intensity reduction measured by a Visual Analog Scale (VAS), with other outcome measurements including the Cox Menstrual Symptom Scale (CMSS), the 12-Item Short Form Health Survey (SF-12) and the Participant Global Impression of Change (PGIC). All assessments will be performed at baseline, each menstrual cycle during the treatment course and the follow-up course. Any adverse events will be recorded throughout the study. DISCUSSION: This is the first study to compare the changes in menstrual pain after three different interventions: the active intervention (AHP), the placebo intervention (APP), and a period of no intervention (WL). This three-arm randomized controlled trial (RCT) aims to investigate the relative contributions of the specific (AHP vs. APP) and non-specific (APP vs. WL) effects to the overall clinical effects of the active AHP on women with PDM. The scientific and rigorous methodology design of this trial should gather good evidence to assess the curative effects and safety of the AHP on PD. Moreover, the results of this study may provide evidence-based references for the treatment of menstrual pain in future. TRIAL REGISTRATION: Chinese Clinical Trial Registry, ID: ChiCTR-TRC-16008701. Registered on 22 July 2016.
引用
- Yu S, Wen Y, Xia W, et al. Acupoint herbal plaster for patients with primary dysmenorrhea: study protocol for a randomized controlled trial. Trials. 2018. PMID: 29970155. doi:10.1186/s13063-018-2682-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。